drugset / Trial / NCT00830063

Tanezumab In Osteoarthritis Of The Knee (2)

NCT00830063

Phase 3 Completed 832 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis.

Timeline

Start
2009-05-05
Primary completion
2010-05-17
Completion
2010-08-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 1000 mg
Subject Tanezumab Monoclonal antibody 5 mg Intravenous
Subject Tanezumab Monoclonal antibody 10 mg Intravenous

Indications